Jeffrey Ubben’s activist firm built its fortunes in part based on its early success with now-struggling Valeant Pharmaceuticals International. With Valeant battling a 90 percent drop in its share price, can ValueAct outrun collateral damage to its reputation?
July 21, 2016
Photo credit: BloombergBy Michelle CelarierValueAct Capital Management’s Jeffrey Ubben has carefully cultivated a reputation as a good-guy activist who works with management to get results — a reputation that was built
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.